On July 9, Alnylam Pharmaceuticals rose 15.34% in regular trading, trading at $361.47/share, with turnover of $640 million.

On the news front, competitor AstraZeneca and its partner Ionis Pharmaceuticals saw their neurology drug Wainua fail to meet the primary endpoint in a late-stage clinical study targeting specific cardiac disease patients. The market widely interpreted this setback as removing a significant competitive obstacle for Alnylam's pipeline products addressing similar indications, or at minimum delaying the direct market challenge it would have faced.

Fundamentally, Alnylam's core product Amvuttra delivered approximately $827 million in net product revenue in the most recent reported quarter, demonstrating validated commercial execution. The sector reaction was pronounced — Ionis Pharmaceuticals fell 17.5% on the same session, while BridgeBio Pharma gained 17.56%, reflecting the competitive reshuffling within the cardiovascular-metabolic space.

Alnylam Pharmaceuticals is an RNAi-based biopharmaceutical company focused on discovering, developing, and commercializing therapeutics that selectively silence specific genes to treat multiple human diseases, with key marketed products including Amvuttra and Onpattro for hereditary transthyretin-mediated amyloidosis.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)